Mast Cell Tryptase Promotes Inflammatory Bowel Disease–Induced Intestinal Fibrosis
- 8 June 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 27 (2) , 242-255
Abstract
Background: Intestinal fibrosis is the final pathological outcome of chronic intestinal inflammation without specific therapeutic drugs, which leads to ileus and surgical intervention. Intestinal fibrosis is characterized by excessive deposition of extracellular matrix (ECM). The role of mast cells (MCs), which are members of the sentinel immune cell population, is unknown in intestinal fibrosis. Methods: In this study, we analyzed changes in MCs, tryptase proteins, and ECM components in human fibrotic and control patient intestines. We constructed dextran sodium sulfate–induced intestinal fibrosis models using wild-type mice, MC-reconstituted mice, and MC-deficient mice to explore the role of MCs and tryptase in intestinal fibrosis. The roles and mechanisms of MCs and tryptase on fibroblasts were evaluated using human MCs (HMC-1 and LAD-2), commercial tryptase proteins, human colon fibroblasts (CCD-18Co fibroblasts), the tryptase inhibitor APC366, and the protease-activated receptor-2 (PAR-2) antagonist ENMD-1068. Results: Regardless of whether the colon was a human colon or a mouse colon, the fibrotic intestinal tissue had increased MC infiltration and a higher expression of ECM proteins or genes than that of the control group. The dextran sodium sulfate–induced intestinal fibrosis in MC-deficient mice was alleviated compared with that in wild-type mice. After MC reconstruction in MC-deficient mice, the alleviating effect disappeared. Tryptase, as a content stored in MC granules, was released into fibrotic intestinal tissues in the form of degranulation, resulting in an increased expression of tryptase. Compared with the control group, the tryptase inhibition group (the APC366 group) had reduced intestinal fibrosis. The CCD-18Co fibroblasts, when cocultured with MCs or treated with tryptase proteins, were activated to differentiate into myofibroblasts and secrete more ECM proteins (such as collagen and fibronectin). The underlying mechanism of fibroblast activation by tryptase was the activation of the PAR-2/Akt/mTOR pathway. Conclusions: We found that MC tryptase promotes inflammatory bowel disease–induced intestinal fibrosis. The underlying mechanism is that tryptase promotes the differentiation of fibroblasts into fibrotic-phenotype myofibroblasts by activating the PAR-2/Akt/ mTOR pathway of fibroblasts.Keywords
Funding Information
- Natural Science Foundation of China (81970565)
- National Natural Science Foundation of China (31741087)
- Shanghai Municipal Science and Technology Commission (18JC1414000)
This publication has 60 references indexed in Scilit:
- Intestinal fibrosis is reduced by early elimination of inflammation in a mouse model of IBD: Impact of a “Top-Down” approach to intestinal fibrosis in miceInflammatory Bowel Diseases, 2012
- Intestinal myofibroblasts: targets for stem cell therapyAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2011
- Amelioration of excess collagen IαI, fibrosis, and smooth muscle growth in TNBS-induced colitis in IGF-I(+/−) miceInflammatory Bowel Diseases, 2011
- Risk Factors Associated With Progression to Intestinal Complications of Crohn's Disease in a Population-Based CohortGastroenterology, 2010
- Intestinal Mesenchymal CellsCurrent Gastroenterology Reports, 2010
- Mast cell-orchestrated immunity to pathogensNature Reviews Immunology, 2010
- Transanal delivery of angiotensin converting enzyme inhibitor prevents colonic fibrosis in a mouse colitis model: development of a unique mode of treatmentSurgery, 2008
- The MyofibroblastThe American Journal of Pathology, 2007
- Formation and Function of the Myofibroblast during Tissue RepairJournal of Investigative Dermatology, 2007
- Fibroblasts in cancerNature Reviews Cancer, 2006